GlassScriptPhysician profile
Kenneth V Summer
NPI 1326032863
$3,682.52
in general payments reported to CMS, 2019-2025
27 companies · $569 in 2025
The $569 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $382 · 2020: $436 · 2021: $364 · 2022: $447 · 2023: $709 · 2024: $776 · 2025: $569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,054.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,054.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $441.22 | 2019-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $428.38 | 2021-2025 | Qelbree, Qelbree |
| Pfizer INC. | $402.68 | 2020-2025 | |
| Cranial Technologies, INC | $290.37 | 2019-2025 | Doc Band |
| Tris Pharma INC | $245.59 | 2019-2024 | Dyanavel Xr |
| Corium, LLC | $235.80 | 2021-2025 | Azstarys |
| Glaxosmithkline, LLC. | $198.38 | 2019-2024 | Bexsero, Rotarix |
| Kaleo, INC. | $176.16 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $153.26 | 2024-2025 | |
| Collegium Pharmaceutical, INC. | $135.18 | 2025 | Jornay Pm |
| Sanofi Pasteur INC. | $127.64 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $124.02 | 2020-2022 | |
| Neos Therapeutics, LP | $121.24 | 2019-2024 | Adzenys Xr-Odt |
| Merck Sharp & Dohme LLC | $118.97 | 2019-2024 | Vaxneuvance, Gardasil 9, Vaxelis |
| Seqirus USA INC | $95.38 | 2022-2025 | Flucelvax, Flucelvax Quadrivalent |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $72.44 | 2024-2025 | Ragwitek, Grastek, Odactra |
| Sobi, INC | $66.12 | 2019-2020 | |
| Verrica Pharmaceuticals INC. | $51.10 | 2024 | Ycanth |
| Shire North American Group INC | $42.44 | 2019 | |
| Alexion Pharmaceuticals, INC. | $37.93 | 2023 | Strensiq |
| Quidel Corporation | $24.56 | 2019 | |
| Pharming Healthcare, INC. | $24.05 | 2023 | Ruconest |
| Neurelis, INC. | $19.06 | 2022 | |
| Rhodes Pharmaceuticals L.P. | $15.81 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.00 | 2024 | |
| Phadia US INC. | $13.96 | 2023 | Immunocap |
| Organon LLC | $6.78 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Summer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.